We are live on
!
Find out more
FFM
Fairmount Funds Management Portfolio holdings
AUM
$1.38B
1-Year Est. Return
407.79%
This Fund
S&P 500
This Quarter
Est. Return
+50.76%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$917M
AUM Growth
-$29.1M
(-3.1%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-25.9%
Top 10 Holdings %
Top 10 Hldgs %
89.15%
Holding
18
New
2
Increased
5
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protagonist Therapeutics
PTGX
|
+$25.4M |
| 2 |
Dianthus Therapeutics
DNTH
|
+$18.1M |
| 3 |
Enliven Therapeutics
ELVN
|
+$16.4M |
| 4 |
Geron
GERN
|
+$14.9M |
| 5 |
Viridian Therapeutics
VRDN
|
+$9.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$176M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$77.5M |
| 3 |
argenx
ARGX
|
+$43M |
| 4 |
Apogee Therapeutics
APGE
|
+$39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$11.8B
| $188M | 20.53% |
2,360,077
| – | – |
|
|
NUVL
2
DELISTED
Nuvalent
NUVL
| $145M | 15.75% |
1,924,626
| – | – |
|
|
3
Apogee Therapeutics
APGE
$10.1B
| $136M | 14.84% |
2,048,647
-892,529
| -30% | -$39M |
|
|
4
Dianthus Therapeutics
DNTH
$5.77B
| $82.9M | 9.03% |
2,762,837
+834,334
| +43% | +$18.1M |
|
5
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $63.2M | 6.89% |
3,204,841
+321,620
| +11% | +$6.28M |
|
|
6
Enliven Therapeutics
ELVN
$3.8B
| $56.3M | 6.14% |
3,202,798
+1,071,429
| +50% | +$16.4M |
|
|
ATXS
7
DELISTED
Astria Therapeutics
ATXS
| $50M | 5.45% |
3,554,129
| – | – |
|
|
8
Viridian Therapeutics
VRDN
$1.99B
| $32.3M | 3.52% |
1,845,813
+476,190
| +35% | +$9.23M |
|
|
MRUS
9
DELISTED
Merus
MRUS
| $32.3M | 3.52% |
717,254
| – | – |
|
10
Cogent Biosciences
COGT
$6.68B
| $31.8M | 3.46% |
4,725,641
+1,166,666
| +33% | +$7.21M |
|
|
11
Protagonist Therapeutics
PTGX
$9.06B
| $27M | 2.94% |
+931,890
| New | +$25.4M |
|
12
Tyra Biosciences
TYRA
$1.91B
| $22.9M | 2.49% |
1,393,329
| – | – |
|
|
13
Geron
GERN
$924M
| $22M | 2.4% |
+6,666,667
| New | +$14.9M |
|
14
Spyre Therapeutics
SYRE
$8.7B
| $14.4M | 1.56% |
378,421
| – | – |
|
|
TERN
15
DELISTED
Terns Pharmaceuticals
TERN
| $13.4M | 1.46% |
2,040,000
| – | – |
|
|
16
argenx
ARGX
$53.8B
| – | – |
-112,903
| Closed | -$43M |
|
|
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – |
-1,245,929
| Closed | -$77.5M |
|
|
IMGN
18
DELISTED
Immunogen Inc
IMGN
| – | – |
-5,929,592
| Closed | -$176M |
|
Similar funds
NIP
OCAM
AU
RIM
VC
AO
1CP
OCM
Fairmount Funds Management's Q1 2024 Portfolio in Review
As of Q1 2024, Fairmount Funds Management held 18 positions worth $917M, down 3.1% from $946M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Fairmount Funds Management withdrew a net $238M in Q1 2024, closing 3 positions and reducing 1 holding. Its most notable exit was Immunogen Inc, an estimated $176M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Fairmount Funds Management opened a new position in Protagonist Therapeutics worth $27M.
- Fairmount Funds Management's largest Q1 2024 buy was Protagonist Therapeutics: 931,890 shares worth $27M.
- Fairmount Funds Management added most to Dianthus Therapeutics in Q1 2024, an estimated $18.1M increase.
- Fairmount Funds Management's biggest Q1 2024 reduction was Apogee Therapeutics, cutting an estimated $39M.
- Fairmount Funds Management fully exited Immunogen Inc in Q1 2024, selling an estimated $176M.
- Fairmount Funds Management's ten largest holdings make up 89% of its $917M portfolio in Q1 2024.
- Fairmount Funds Management opened 2 new positions and closed 3 in Q1 2024.
- Fairmount Funds Management's portfolio value fell 3.1% quarter-over-quarter to $917M.
Based on Fairmount Funds Management's 13F filing for Q1 2024, filed 15 May 2024.